Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
Metabolism. 2020 Dec;113:154405. doi: 10.1016/j.metabol.2020.154405. Epub 2020 Oct 16.
The crosstalk between sodium-glucose cotransporter 2 (SGLT2) inhibition and a membrane-associated endocytic receptor megalin function involved in renal proximal tubular protein overload in progressive diabetic nephropathy (DN) is uncertain. Here, we determined whether SGLT2 inhibition affects megalin endocytic function through suppressing its O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) and protects the diabetic kidney from protein overload.
We treated 8-week-old male non-obese and hypoinsulinemic KK/Ta-Ins2 (KK/Ta-Akita) mice which develop progressive DN with an SGLT2 inhibitor ipragliflozin or insulin for 6 weeks, and investigated the endocytic function (proximal tubular protein reabsorption), renal expression and O-GlcNAcylation of megalin along with their effects on renal phenotypes including histology and biochemical markers.
The treatment with ipragliflozin, but not insulin, suppressed megalin O-GlcNAcylation and accelerated its internalization, resulting in reduction in proximal tubular reabsorption of the highly filtered plasma proteins such as albumin and neutrophil gelatinase-associated lipocalin. These alterations following the ipragliflozin treatment contributed to amelioration of proximal tubular protein overload, mitochondrial morphological abnormality, and renal oxidative stress and tubulointerstitial fibrosis.
The present study provides a novel crosstalk mechanism between SGLT2 inhibition and megalin underlying the potential renal benefits of SGLT2 inhibition in DN.
在进行性糖尿病肾病(DN)中,钠-葡萄糖共转运蛋白 2(SGLT2)抑制与参与近端肾小管蛋白过载的膜相关内吞受体 megalin 功能之间的串扰尚不清楚。在这里,我们通过抑制其 O-连接的 β-N-乙酰氨基葡萄糖修饰(O-GlcNAcylation)来确定 SGLT2 抑制是否会影响 megalin 的内吞作用,并保护糖尿病肾脏免受蛋白过载。
我们用 SGLT2 抑制剂 ipragliflozin 或胰岛素处理 8 周龄的非肥胖和低胰岛素血症 KK/Ta-Ins2(KK/Ta-Akita)雄性小鼠,这些小鼠会发展为进行性 DN,持续 6 周,并研究了 megalin 的内吞作用(近端肾小管蛋白重吸收)、肾脏表达和 O-GlcNAcylation 及其对肾脏表型的影响,包括组织学和生化标志物。
ipragliflozin 治疗而非胰岛素治疗可抑制 megalin 的 O-GlcNAcylation 并加速其内化,从而减少高度过滤的血浆蛋白(如白蛋白和中性粒细胞明胶酶相关脂质运载蛋白)的近端肾小管重吸收。ipragliflozin 治疗后的这些变化有助于改善近端肾小管蛋白过载、线粒体形态异常、肾脏氧化应激和肾小管间质纤维化。
本研究提供了 SGLT2 抑制和 megalin 之间的一种新的串扰机制,为 SGLT2 抑制在 DN 中的潜在肾脏益处提供了新的机制。